Literature DB >> 2095345

Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults.

J J van Meyel1, Y Tan, P Smits, F G Russel, C A van Ginneken, F W Gribnau.   

Abstract

The absorption and diuretic effect of furosemide 40 mg alone (F), and of the free (F + T) and the fixed (FT) combinations of furosemide 40 mg and triamterene 50 mg have been compared in 12 healthy young men. A slight reduction in the area under the concentration-time curve (AUC) of plasma furosemide was found for the fixed combination (AUC480) F2.58 micrograms.h.ml-1; F + T 2.46 micrograms.h.ml-1; FT 1.97 micrograms.h.ml-1. There was a significant reduction in the AUC480 of plasma triamterene (F + T 204.9 micrograms.h.l-1; FT 130.2 micrograms.h.l-1). Sodium excretion after F + T and FT was more pronounced than after F (F + T 302 mmol; FT 311 mmol; F259 mmol). When compared to F alone, there was a reduction in the 24-hour potassium excretion after F + T as well as after FT (F 121 mmol; F + T 104 mmol; FT 107 mmol). It is concluded that the absorption of triamterene was significantly reduced after ingestion of the fixed combination tablet. However, in healthy male adults this had no influence on its natriuretic and potassium-sparing effect as compared to the free combination.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095345     DOI: 10.1007/bf00316104

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Effects of triamterene on serum and skeletal muscle electrolytes in diuretic-treated patients.

Authors:  L Widmann; T Dyckner; P O Wester
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Solid-phase extraction of furosemide from plasma and urine and subsequent analysis by high-performance liquid chromatography.

Authors:  F G Russel; Y Tan; J J Van Meijel; F W Gribnau; C A Van Ginneken
Journal:  J Chromatogr       Date:  1989-11-10

3.  Comparison of the efficacy of furosemide with two furosemide-triamterene combinations in the treatment of cardiac insufficiency.

Authors:  H Saarimaa; T Ojasalo
Journal:  J Int Med Res       Date:  1985       Impact factor: 1.671

4.  Preliminary observations on dissolution and bioavailability of triamterene-hydrochlorothiazide combination products.

Authors:  V P Shah; M A Walker; V K Prasad; J Lin; G Knapp; B E Cabana
Journal:  Biopharm Drug Dispos       Date:  1984 Jan-Mar       Impact factor: 1.627

5.  Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered.

Authors:  R A Upton; R L Williams; E T Lin; W L Gee; C D Blume; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

6.  Effectiveness of potassium chloride or triamterene in thiazide hypokalemia.

Authors:  V Papademetriou; J Burris; S Kukich; E D Freis
Journal:  Arch Intern Med       Date:  1985-11

7.  Potassium/magnesium depletion in patients with cardiovascular disease.

Authors:  T Dyckner; P O Wester
Journal:  Am J Med       Date:  1987-03-20       Impact factor: 4.965

8.  Relative potency of spironolactone, triamterene and potassium chloride in thiazide-induced hypokalaemia.

Authors:  P R Jackson; L E Ramsay; V Wakefield
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

9.  Diuretic-induced ventricular ectopic activity.

Authors:  O B Holland; J V Nixon; L Kuhnert
Journal:  Am J Med       Date:  1981-04       Impact factor: 4.965

Review 10.  Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.

Authors:  M Hammarlund-Udenaes; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-02
View more
  1 in total

1.  Absorption of high dose furosemide (frusemide) in congestive heart failure.

Authors:  J J Van Meyel; P G Gerlag; P Smits; F G Russel; Y Tan; C A Van Ginneken; F W Gribnau
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.